Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Antonio Iaffaldano"'
Autor:
Damiano Paolicelli, Maddalena Ruggieri, Alessia Manni, Concetta D. Gargano, Graziana Carleo, Claudia Palazzo, Antonio Iaffaldano, Luca Bollo, Tommaso Guerra, Annalisa Saracino, Antonio Frigeri, Pietro Iaffaldano, Maria Trojano
Publikováno v:
Brain Sciences, Vol 12, Iss 12, p 1595 (2022)
Although cladribine induces sustained reductions in peripheral T and B lymphocytes, little is known about its effect on axonal damage reduction in multiple sclerosis (MS), which could be demonstrated by assessing the serum neurofilament light chain (
Externí odkaz:
https://doaj.org/article/cde8d1a204b04d32a374c572815f66c7
Autor:
Alessia Manni, Antonio Iaffaldano, Giuseppe Lucisano, Mariangela D'Onghia, Domenico Maria Mezzapesa, Vincenzo Felica, Pietro Iaffaldano, Maria Trojano, Damiano Paolicelli
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Introduction: In relapsing Multiple Sclerosis (RMS) patients treated with disease modifying drugs (DMDs), few data are available regarding the biomarkers of treatment response. We aimed to assess the predictive value of lymphocyte count (LC) and Body
Externí odkaz:
https://doaj.org/article/54b0495983f247138d7789d79c943a87
Autor:
Damiano Paolicelli, Alessia Manni, Antonio Iaffaldano, Giusy Tancredi, Katia Ricci, Eleonora Gentile, Rosa Gemma Viterbo, Silvia Giovanna Quitadamo, Marina de Tommaso, Maria Trojano
Publikováno v:
Brain Sciences, Vol 11, Iss 4, p 481 (2021)
Cognitive impairment (CI) is a common and disabling symptom of Multiple Sclerosis (MS) with a negative impact on daily living. In this pilot study, we applied magnetoencephalography (MEG) and high density (hd) electroencephalography (EEG) study to ev
Externí odkaz:
https://doaj.org/article/e62f9067cf6540f4be1646cd075d006c
Autor:
Damiano Paolicelli, Sergio Iannazzo, Laura Santoni, Antonio Iaffaldano, Valentina Di Lecce, Alessia Manni, Vito Lavolpe, Carla Tortorella, Mariangela D'Onghia, Vita Direnzo, Elisa Puma, Maria Trojano
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159214 (2016)
Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased
Externí odkaz:
https://doaj.org/article/b50de5d8f6044883899f27b134f50cbf
Autor:
Valeria Albano, Rosanna Dammacco, Alessia Manni, Dario Sisto, Antonio Iaffaldano, Alberto Mavilio, Giovanni Alessio, Maria Trojano, Damiano Paolicelli
Publikováno v:
European journal of ophthalmology. 33(1)
Purpose Spectral-domain optical coherence tomography (SD-OCT) was used to evaluate, in patients with multiple sclerosis without a history of optic neuritis (MSNON), the proportion of the different macular ganglion cell-inner plexiform layer complex (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dc9177e978ccff6f2051fec790d9e94
https://pubmed.ncbi.nlm.nih.gov/35799453
https://pubmed.ncbi.nlm.nih.gov/35799453
Autor:
Eleonora Gentile, Giusy Tancredi, Rosa Gemma Viterbo, Katia Ricci, Damiano Paolicelli, Silvia Giovanna Quitadamo, Antonio Iaffaldano, Maria Trojano, Alessia Manni, Marina de Tommaso
Publikováno v:
Brain Sciences
Volume 11
Issue 4
Brain Sciences, Vol 11, Iss 481, p 481 (2021)
Volume 11
Issue 4
Brain Sciences, Vol 11, Iss 481, p 481 (2021)
Cognitive impairment (CI) is a common and disabling symptom of Multiple Sclerosis (MS) with a negative impact on daily living. In this pilot study, we applied magnetoencephalography (MEG) and high density (hd) electroencephalography (EEG) study to ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3713b442ab44a8ff7b3a9e5694e917ee
http://europepmc.org/articles/PMC8069556
http://europepmc.org/articles/PMC8069556
Publikováno v:
CNS drugs. 34(1)
Disease-modifying therapies have now become standard treatment for multiple sclerosis. These include five oral therapies for relapsing-remitting multiple sclerosis, namely fingolimod, dimethyl fumarate, teriflunomide, cladribine, and siponimod, altho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4379ebb72ebe407dbbcba5ccb93708
https://pubmed.ncbi.nlm.nih.gov/31898276
https://pubmed.ncbi.nlm.nih.gov/31898276
Autor:
Antonella Conte, Daniele Spitaleri, Vincenzo Brescia Morra, Marco Rovaris, Giacomo Lus, Francesca De Robertis, Carlo Avolio, Giovanna De Luca, Mauro Zaffaroni, Claudio Gasperini, Damiano Paolicelli, Paola Gazzola, Alessia Manni, Eleonora Cocco, Pietro Iaffaldano, Giancarlo Comi, Marco Salvetti, Ilaria Pesci, Antonio Iaffaldano, Giorgia Teresa Maniscalco, Maria Pia Amato, Maurizia Gatto, Carlo Pozzilli, Maria Trojano, Francesco Patti, Marco Capobianco, Giuseppe Salemi, Girolama Alessandra Marfia, Giuseppe Lucisano, Davide Maimone, Rocco Totaro, Simona Bonavita, Giulia Mallucci
The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of different treatment sequences is not well established. This is particularly relevant for MS p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0388be57c3084f240260f30bb2b67cac
http://hdl.handle.net/11591/415383
http://hdl.handle.net/11591/415383
Autor:
Vita Direnzo, Valentina Di Lecce, Damiano Paolicelli, Antonio Iaffaldano, Stefano Zoccolella, Maria Trojano, Alessia Manni, Carla Tortorella, Mariangela D'Onghia
Publikováno v:
The Journal of Clinical Pharmacology. 56:845-851
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was approved as add-on therapy for spasticity in patients with multiple sclerosis (MS). We show our 40-week postmarketing experience regarding efficacy and safety of THC/CBD spray
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374df8a7eec0ac68b28f2c836b1d5cbf
https://doi.org/10.1002/jcph.670
https://doi.org/10.1002/jcph.670
Autor:
Caroline Airey, Ilya Ayzenberg, Sami L. Bahna, Shyamal C. Bir, Stefan Blum, Alexandria L. Brackett, J. Nicholas Brenton, Erik V. Burton, Michelle H. Cameron, Roxana O. Carare, Oleg Y. Chernyshev, Andrew L. Chesson, Tanuja Chitnis, Himanshu Chokhawala, Jan Damoiseaux, Debra E. Davis, Fariba Dehghanian, Alexandre do Couto e Silva, Donard S. Dwyer, Meredith C. Frederick, David Gillis, Neetu Godhwani, Grace Gombolay, Daniel N. Granger, Yathish Haralur, Zohreh Hojati, Tsung-Han Hsieh, Raymond Hupperts, Antonio Iaffaldano, Piyush Kalakoti, Elaheh Kamali, Merve Kasap, Maryam Kay, Roger E. Kelley, Brian P. Kelley, Ingo Kleiter, Reggie H.C. Lee, Michelle H.H. Lee, Hung Wen Lin, Amy E. Lovett-Racke, Alessia Manni, Sheryl Martin-Schild, Nicholas E. Martinez, Amir Mazhari, David E. McCarty, Laszlo Mechtler, Alireza Minagar, Sarthak Mittal, Nafiseh Moeinifar, Abdureza N. Moghadasi, Majid Motovali-Bashi, Nasrin Nabavizadeh, Mutsumi Nagai, Anil Nanda, Digvijaya Navalkele, Samira Navardi, Martin Newman, Michael Nichtweiß, Seiichi Omura, Damiano Paolicelli, Nandor Pinter, Harlee Possoit, Michael K. Racke, Reza Rahmanzadeh, Christina R. Reynolds, Kourosh Rezania, Mohammad A. Sahraian, Fumitaka Sato, James G. Scott, Kanika Sharma, Joost Smolders, Hai Sun, Corinna Trebst, Ikuo Tsunoda, Charoskhon Turabova, Stefan Weidauer, Roy O. Weller, Richard C. Wong, Celeste Y.C. Wu, Paolo Zamboni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49e1b23452add271c7354d180f8d6ad
https://doi.org/10.1016/b978-0-12-811709-5.00047-8
https://doi.org/10.1016/b978-0-12-811709-5.00047-8